Clinical Trial Update: Acalabrutinib in Combination With Venetoclax for the Treatment of Refractory or Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, The AVENUE-2 Trial [Phase 2]

View source ↗

Summary

The AVENUE-2 Phase 2 trial investigates acalabrutinib in combination with venetoclax for patients with refractory or recurrent chronic lymphocytic leukemia or s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Acalabrutinib (Calquence) (acalabrutinib)
• Venetoclax (Venclyxto) (venetoclax)

Snippet

Sponsor: Fred Hutchinson Cancer Center | Conditions: Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma | Phase 2 | Status: RECRUITING